This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Peter R. Joyce, MB, ChB, FRANZCP; Eugene S. Paykel, MA, MD, FRCPsych, FRCP

Arch Gen Psychiatry. 1989;46(1):89-99.

Abstract
• Although the major classes of antidepressant drugs have been available for over 30 years, clinicians are still unable to predict accurately the response of their depressed patients to medication. This article reviews both clinical and biologic predictors of treatment response and makes recommendations for future studies. The tricyclic antidepressants remain the drugs of choice in major depressive disorders. Lithium has a place in bipolar depressions. Monoamine oxidase inhibitors have a role in depressions accompanied by marked anxiety and/or panic symptoms, in patients who have previously responded to them, and as a second-choice treatment in those depressed patients who have not responded to tricyclic antidepressants. Electroconvulsive therapy or additional antipsychotic drugs are frequently necessary in very severe and delusional depressions. Biologic predictors of response, despite some interesting leads that may in the long term be of considerable importance, are not yet sufficiently established to be of routine clinical usefulness, although either dexamethasone nonsuppression or a shortened rapid eye movement latency may identify depressed patients who require biologic treatment.

Author Affiliations
From the University Department of Psychological Medicine, Christchurch (New Zealand) School of Medicine, Sunnyside Hospital (Dr Joyce); and Department of Psychiatry, University of Cambridge (England), Addenbrooke's Hospital (Dr Paykel).

Footnotes
Accepted for publication April 15, 1988.

Reprint requests to University Department of Psychological Medicine, Christchurch School of Medicine, Sunnyside Hospital, Christchurch, New Zealand (Dr Joyce).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Impact of Tryptophan Metabolism on the Vulnerability to Alcohol-Related Blackouts and Violent Impulsive Behaviours
Vignau et al.
Alcohol Alcohol 2009;0:agp044v1-agp044.
ABSTRACT | FULL TEXT  

Patient Predictors of Response to Psychotherapy and Pharmacotherapy: Findings in the NIMH Treatment of Depression Collaborative Research Program
Sotsky et al.
Focus 2006;4:278.
ABSTRACT | FULL TEXT  

Evaluation of Outcomes With Citalopram for Depression Using Measurement-Based Care in STAR*D: Implications for Clinical Practice
Trivedi et al.
Am. J. Psychiatry 2006;163:28-40.
ABSTRACT | FULL TEXT  

Efficacy of antidepressants in adults
Moncrieff and Kirsch
BMJ 2005;331:155-157.
FULL TEXT  

A Reappraisal of Atypical Depression
QUITKIN et al.
Am. J. Psychiatry 2003;160:798-800.
FULL TEXT  

Atypical Depression: A Reappraisal
Parker et al.
Am. J. Psychiatry 2002;159:1470-1479.
ABSTRACT | FULL TEXT  

Classification, disability and the public health agenda: Depression and public health
Lewis and Araya
Br Med Bull 2001;57:3-15.
ABSTRACT | FULL TEXT  

A Placebo-Controlled Study of Fluoxetine Versus Imipramine in the Acute Treatment of Atypical Depression
McGrath et al.
Am. J. Psychiatry 2000;157:344-350.
ABSTRACT | FULL TEXT  

Treatment of Major Depression With Psychotherapy or Psychotherapy-Pharmacotherapy Combinations
Thase et al.
Arch Gen Psychiatry 1997;54:1009-1015.
ABSTRACT  

The Identification and Validation of Distinct Depressive Syndromes in a Population-Based Sample of Female Twins
Quitkin et al.
Arch Gen Psychiatry 1997;54:970-972.
ABSTRACT  

Clinical and Biochemical Effects of Catecholamine Depletion on Antidepressant-Induced Remission of Depression
Miller et al.
Arch Gen Psychiatry 1996;53:117-128.
ABSTRACT  

Critical flicker fusion threshold and anticholinergic effects of chronic antidepressant treatment in remitted depressives
Hale and Pinninti
J Psychopharmacol 1995;9:258-266.
ABSTRACT  

Commentary on the management of treatment-resistant affective disorder: clinical perspectives
Potter and Manji
J Psychopharmacol 1992;6:164-166.
 

Response to Phenelzine and Imipramine in Placebo Nonresponders With Atypical Depression: A New Application of the Crossover Design
Quitkin et al.
Arch Gen Psychiatry 1991;48:319-323.
ABSTRACT  

Atypical Depression, Panic Attacks, and Response to Imipramine and Phenelzine: A Replication
Quitkin et al.
Arch Gen Psychiatry 1990;47:935-941.
ABSTRACT